
    
      The primary end point in this study is appointed to be "Helicobacter pylori infection
      eradication with TRIOL treatment" and the secondary end point as "safety". The study involves
      the investigation of the efficacy and safety of the triple treatment consisting of 500 mg
      levofloxacin, 1000 mg amoxicillin and 30 mg lansoprazole on Helicobacter pylori eradication
      in 60 patients with Helicobacter pylori infection.
    
  